In vitro experiments demonstrated significant inhibition of α-glucosidase and α-amylase by scopoletin, suggesting its anti-diabetic potential.
Diabetes mellitus is a metabolic disorder, and controlling blood glucose levels is a key strategy in managing the condition and preventing its complications. One therapeutic approach involves the use of drugs that inhibit enzymes responsible for carbohydrate digestion, as well as agents that reduce glucose absorption from the bloodstream. This study aimed to investigate, through in vitro experiments, whether scopoletin could inhibit the activity of key carbohydrate-digesting enzymes, such as α-glucosidase and α-amylase. The results demonstrated that scopoletin significantly inhibited both α-glucosidase and α-amylase activity, indicating its potential antidiabetic properties. In addition to its antidiabetic effects, scopoletin is also known for its anti-inflammatory, anticancer, antimicrobial, hepatoprotective, neuroprotective, and antioxidant properties.
No takes yet. Share an insight, caveat, or question.
Danamurthy et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: